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Preface
Over the last few decades the role of statistics in the evaluation and interpretation
of clinical data has become more and more important. As a result the standards of
clinical study design, conduct and interpretation have been advanced. In this book
statistical considerations in data analysis as a basis for deriving an accurate clinical
interpretation are elaborated.
Most often it is the physician who decides whether to prescribe a specific drug for
a specific patient in a specific situation. The decisions of the physicians are largely
based on the interpretation of data they have read and heard. This book describes
various ways of approaching and interpreting the data that result from a clinical trial
study.
The book reemphasizes the essential role that biostatistics plays in clinical
trials. The book contains 18 carefully reviewed chapters on recent developments
in trials and statistics. The chapters in this book are generally autonomous and
may be read in any order. Each chapter is written by one or more experts in the
specific approach. Starting from (a) some background information about the specific
approach (short history and main publications), the chapter (b) describes the type
of research questions the approach is able to answer and the kind of data to be
collected, (c) gives the statistical and mathematical explanation of the model(s) used
in the analysis of the data, (d) discusses the input and output of the software used in
the analysis, and (e) provides one or more examples with typical data sets enabling
the readers to apply the programs themselves. The chapters are worked out in a
homogeneous style to enhance comparability between the approaches. The data sets
and the computer code for the analysis with various softwares are a very important
component of the book. They are available upon request (by emailing the authors of
the chapters).
Each chapter is self-contained in this edited volume. The chapters are written and
reviewed by experts in the specific approach. Although an authored volume could
have advantages, because of the rapid changes in the field, an edited book written
by people who are in the middle of the latest developments in the specific approach
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is preferable. In addition, the authors of the chapters use a shared notation to enable
the reader to compare methods more easily.
The book addresses the great majority of researchers in the field of clinical
trials. Included are biostatisticians, medical researchers and physicians. It is meant
as a reference work for all those actually doing and using research in the field
of clinical trials. To reach this vast audience, knowledge of statistics as taught at
master degree level in medical and biomedical sciences is required. However, the
restricted number of chapters gives each of the chapters the opportunity to go into
sufficient details to enable the readers to understand and apply the methods. In
addition, the book addresses biostatisticians and physicians, who are professionally
dealing with research in the field of clinical trials, to provide standards for state-
of-the-art practices. Furthermore, the book offers researchers new ideas about the
use of biostatistical analysis in solving their research problems. Finally the book
is suitable as obligated literature for courses in clinical trial evaluation given at
university medical and epidemiological research schools.
We thank the authors of the chapters for their willingness to contribute to the
book, the anonymous reviewers for their expertise and time invested and Springer
Publishers for their decision to publish the book in their Statistics book program.
Rotterdam, The Netherlands Kees van Montfort
Nijmegen, The Netherlands Johan Oud
Rotterdam, The Netherlands Wendimagegn Ghidey
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